With the shared goal of decreasing patient’s treatment burden, multiple anti-VEGF drugs have emerged with innovative modalities designed to achieve increased efficacy, durability and treatment interval while maintaining a relatively safe treatment profile in managing retinal disease [1–4, 25]. This evidence concerns the gene VEGFA and Abnormal retinal morphology.